← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Micafungin

FDA approved · Rx

Echinocandin antifungal

Also known as: Mycamine, Micafungin In Sodium Chloride, micafungine, Micafungina, micafunginum

Evidence score
95/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 71 registered studies on ClinicalTrials.gov, most advanced Phase 4
  • 2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Micafungin, sold as Mycamine and generic versions, is a semisynthetic cyclic lipopeptide antifungal in the echinocandin class. It works by blocking the enzyme 1,3-beta-D-glucan synthase, which fungi need to build their cell walls, weakening the cell wall of susceptible fungi such as Candida.

What the evidence shows

Automatic summaryHuman trials

Micafungin is FDA-approved as a prescription intravenous drug, approved for treating candidemia and certain invasive Candida infections, esophageal candidiasis, and for preventing Candida infections in some stem cell transplant patients. Its use is supported by a large body of human research, including 71 registered trials reaching Phase 4 and over 2,000 published papers.

Key facts

Molecular formula
C56H71N9O23S
Molecular weight
1270.3 g/mol
FDA approval
Confirmed on openFDA

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

71registered studies
Phase 4most advanced phase
46completed (sample)
0recruiting (sample)

A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia

Phase 4TerminatedNCT01982071

Micafungin Pharmacokinetics in Obese Patients

Phase 4CompletedNCT03102658

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Phase 3TerminatedNCT05178862

PEACE: Pediatric Antifungal Comparative Effectiveness

CompletedNCT01869829

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

2,409papers referencing Micafungin

Echinocandin antifungal drugs.

Lancet2003

Twenty Years of the SENTRY Antifungal Surveillance Program: Results for <i>Candida</i> Species From 1997-2016.

Open Forum Infect Dis2019

Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.

Clin Infect Dis2013

Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins.

Antimicrob Agents Chemother2002

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.